French pharmaceutical maker Sanofi-Aventis SA spent $870,000 in the second quarter lobbying the U.S. government on prescription drug issues and other items, according to a recent disclosure form.
That marks a 45 percent reduction from the $1.58 million it spent in the same period in 2009 and in the first quarter.
The company's biggest-selling product is the diabetes treatment Lantus. It also makes vaccines and the blood thinner Plavix, which currently faces generic competition.
Sanofi-Aventis lobbied on bills focusing on health reform issues, tax credits for pharmaceutical companies and drug pricing, according to the filing with the House clerk's office on July 20.
No comments:
Post a Comment